VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COMy Virtual 2020 | Synergy: MCL-1 & BCL-2 inhibition for myeloma

Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, discusses the simultaneous inhibition of MCL-1 and BCL-2 with the combination with S63845 and venetoclax for the treatment of myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter